ERBB2 and neoplasm: Significant differences were observed in SBR grade (p < 0.0001), tumor stage (p < 0.0001), tumor size (p < 0.0001), Ki-67 (HR-negative: p = 0.004, HR-positive: p < 0.0001), and lymph node involvement (HR negative: p < 0.0001, HR-positive: p = 0.004) when comparing the clinicopathological characteristics with HER2 subtypes in considering the HR status.